Rapid and sustained resolution in generalized pustular psoriasis with IL‐17A inhibitors required high adherence: a 96‐week analysis in a real‐life setting

Documenti analoghi

• The impacts of biologic treatment on metabolic profiling in psoriasis
  di: Sichun Deng, et al.
  Pubblicazione: (2024)
• Increased neutrophil‐derived IL‐17A identified in generalized pustular psoriasis
  di: Yu Lan, et al.
  Pubblicazione: (2024)
• Recibokibart, an anti‐IL‐36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial
  di: Qiaoxia Qian, et al.
  Pubblicazione: (2025)
• Sclerosing cholangitis exacerbated by widespread pustular psoriasis
  di: Akane Ogaya, et al.
  Pubblicazione: (2024)
• Regional differences in the prevalence of generalized pustular psoriasis in Japan
  di: Hideki Fujita, et al.
  Pubblicazione: (2024)